Creative BioMolecules, Inc. is a biopharmaceutical company
focused on the discovery and development of therapies for human tissue regeneration and
repair. The Company's therapies are based on bone morphogenetic proteins (BMPs) that act
in initiating and regulating the cellular events involved in the development and repair of
human tissues and organs.
Creative BioMolecules' lead product, a bone
graft substitute, has completed a U.S. 
pivotal clinical trial. The bone
graft substitute is designed to promote new bone growth to heal severe fractures.
Additional products in development include therapies for kidney
failure, and stroke and other neurological disorders. The
Company’s research focus is also directed toward the discovery of new therapeutic
applications of its morphogenic proteins and the understanding of signaling pathways to
develop small molecules based on the biology of these proteins.
The Company has a strong portfolio of issued
patents and patent applications that provides broad protection for product development
with multiple proteins in many therapeutic fields.
